Advertisement
The interview will cover topics including RxElite's market potential,growth initiatives, competitive edge, recent news, and milestones for whichinvestors should watch. To hear the interview in its entirety, visithttp://www.wallst.net, and click on "Interviews." The interview can beaccessed either by locating the company's ticker symbol under the appropriateexchange on the left-hand column of the "Interviews" section of the site, orby entering the company's ticker symbol in the Search Archive window once itis posted.
Advertisement
About RxElite Holdings, Inc.
RxElite Holdings, Inc. develops, manufactures, and markets genericprescription drug products in specialty generic markets. These markets includeproducts in the areas of anesthesia, sterile liquid dose drugs (includingrespiratory inhalation drugs, ophthalmics, and injectable drugs), andtransdermal patch products.
The full details of the transactions described in this press release canbe found in our filings with the Securities and Exchange Commission.
For interviews with RxElite CEO Daniel Chen, or for inquiries related toinvestor relations, please contact Charlie Forshee at 215-885-4981.
SOURCE Financial Filings Corp.
